{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for alpha root_references_url in (root_references_url (approximate match)
Status:
US Approved Rx
(2023)
Source:
BLA761278
(2023)
Source URL:
First approved in 2023
Source:
BLA761278
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:exidavnemab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02672163: Not Applicable Interventional Completed Heart Failure
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00278174: Phase 2 Interventional Completed Kidney Cancer
(2005)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00537420: Phase 2 Interventional Completed Obesity
(2007)
Source URL:
Class:
PROTEIN